Diarrheal diseases remain a leading cause of illness and death among young children in low-income countries. A major culprit is Enterotoxigenic Escherichia coli, commonly known as ETEC. A groundbreaking phase 2b clinical trial recently published in The Lancet Infectious Diseases reveals that an experimental oral E. coli vaccine called ETVAX can safely and effectively reduce episodes of moderate to severe ETEC-related diarrhea in infants.
Developed by Scandinavian Biopharma, ETVAX is currently the most clinically advanced vaccine targeting this dangerous bacterium. Researchers emphasize that a successful oral E. coli vaccine could prevent millions of infections, reduce hospital admissions, and help curb the growing crisis of antimicrobial resistance in regions with high infection rates.
Phase 2b Trial Evaluates Efficacy in Young Children
To test the vaccine’s effectiveness, investigators conducted a randomized, double-blind, placebo-controlled trial in Gambia. The study enrolled 4,936 children between the ages of six and 18 months living in an area where the bacterium is endemic. Participants were divided evenly, receiving either the experimental vaccine or a placebo across three scheduled doses administered on days one, 15, and 90.
The primary goal of the study was to measure protection against the first episode of laboratory-confirmed, moderate to severe ETEC diarrhea, specifically excluding cases involving coinfections with other pathogens.
Researchers found that the vaccine offered a statistically significant level of protection. While the initial efficacy for the strict primary endpoint was 26.6 percent, the protection levels increased dramatically under different analytical conditions. When looking at moderate to severe ETEC diarrhea regardless of other co-infecting pathogens, efficacy reached 48.2 percent. Furthermore, when researchers excluded cases involving intestinal parasites, the vaccine’s effectiveness soared to 80.6 percent.
Age also played a crucial role in the vaccine’s success. Infants who received their first dose before reaching nine months of age experienced a 67.8 percent reduction in all moderate to severe ETEC diarrhea cases.
Triggering Strong Immune Defenses
ETVAX is designed as an oral, inactivated whole-cell vaccine. It works by teaching the immune system to recognize and fight off multiple ETEC colonization factors and toxins. During the trial, a subset of 122 children underwent specific immunogenicity testing to measure these biological responses.
The results demonstrated that the oral E. coli vaccine successfully triggered both mucosal and systemic antibody defenses. The immunized children showed increased antibodies specifically directed against bacterial colonization factors and heat-labile toxins. These specific toxins are responsible for stimulating fluid secretion in the intestines, which leads to sudden and severe watery diarrhea. By blocking the bacteria from attaching to the intestinal walls and neutralizing these harmful toxins, the vaccine directly addresses the core mechanisms that cause severe illness.
Excellent Safety Profile for Infants
Safety is always a primary concern when evaluating new medical treatments for infants and toddlers. Throughout the clinical trial, researchers closely monitored all participants for adverse reactions. The safety outcomes were highly encouraging for public health officials.
Serious adverse events were rare and occurred at nearly identical rates in both groups. Only 1.0 percent of the children receiving ETVAX experienced a serious health event, compared to 1.3 percent in the placebo group. Crucially, investigators determined that none of these serious adverse events in either group were related to the vaccine itself. Overall, the vaccine was well-tolerated, confirming a reassuring safety profile for this vulnerable age demographic.
Addressing a Major Global Health Threat
Every year, ETEC causes an estimated 75 million episodes of diarrhea and is linked to up to 42,000 deaths among children under five in low-income nations. The intense watery diarrhea caused by the infection frequently leads to severe dehydration, which can be fatal if left untreated by medical professionals.
Beyond the immediate threat to life, repeated diarrheal infections during early childhood can cause severe long-term harm. Frequent illness is strongly associated with stunted physical growth, impaired cognitive development, and a higher vulnerability to other infectious diseases. With changing global climates predicted to increase the incidence of ETEC infections, the need for a preventive solution is becoming increasingly urgent.
Looking Ahead to Phase 3 Trials
The study’s authors consider these findings to be the first demonstration that ETVAX can induce protective efficacy in at-risk young children. The positive results regarding both safety and biological effectiveness pave the way for the next critical stage of medical research and development.
Investigators have confirmed that the data strongly supports advancing to a large, multi-country phase 3 clinical trial. This upcoming research phase will seek to confirm the vaccine’s efficacy across diverse global populations and further evaluate its potential public health benefits. If the phase 3 trials are successful, it could lead to the widespread introduction of this vital medical intervention in high-burden settings around the world, saving countless lives.
